Zobrazeno 1 - 10
of 425
pro vyhledávání: '"Takayuki Kondo"'
Autor:
Hidefumi Suzuki, Naohiro Egawa, Keiko Imamura, Takayuki Kondo, Takako Enami, Kayoko Tsukita, Mika Suga, Yuichiro Yada, Ran Shibukawa, Ryosuke Takahashi, Haruhisa Inoue
Publikováno v:
Molecular Brain, Vol 17, Iss 1, Pp 1-14 (2024)
Abstract Synucleinopathies refer to a group of disorders characterized by SNCA/α-synuclein (α-Syn)-containing cytoplasmic inclusions and neuronal cell loss in the nervous system including the cortex, a common feature being cognitive impairment. Sti
Externí odkaz:
https://doaj.org/article/e2c171af79924b389b070d5267a36739
Autor:
Takayuki Kondo, Kentaro Fujimoto, Kisako Fujiwara, Sae Yumita, Takamasa Ishino, Keita Ogawa, Miyuki Nakagawa, Terunao Iwanaga, Keisuke Koroki, Hiroaki Kanzaki, Masanori Inoue, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Sadahisa Ogasawara, Shingo Nakamoto, Tetsuhiro Chiba, Jun Kato, Keiichi Fujiwara, Naoya Kato
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract The pathogenesis of acute liver failure (ALF) involves cell death. Necroptosis is a newly suggested programmed cell death, and receptor-interacting protein kinase 3 (RIPK3) has been reported as a marker for necroptosis. However, there are fe
Externí odkaz:
https://doaj.org/article/3e4e126c68c14363a57501f3cba46624
Autor:
Masanori Inoue, Sadahisa Ogasawara, Kazufumi Kobayashi, Tomomi Okubo, Norio Itokawa, Masamichi Obu, Kentaro Fujimoto, Hidemi Unozawa, Sae Yumita, Kisako Fujiwara, Miyuki Nakagawa, Hiroaki Kanzaki, Keisuke Koroki, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Takayuki Kondo, Shingo Nakamoto, Kengo Nagashima, Ei Itobayashi, Masanori Atsukawa, Yoshihiro Koma, Ryosaku Azemoto, Naoya Kato
Publikováno v:
Liver Cancer, Pp 1-1 (2024)
Introduction: Macrovascular invasion (MVI) is a strong prognostic factor for advanced hepatocellular carcinoma (HCC). The current criteria for radiological assessment are unclear in evaluating the impact of MVI on systemic therapy. In this study, we
Externí odkaz:
https://doaj.org/article/c53294c0a6fc47be8eb613a0ebe4f0a7
Autor:
Hiroaki Kanzaki, Sadahisa Ogasawara, Tomomi Okubo, Norio Itokawa, Ryohei Yoshino, Kentaro Fujimoto, Tadayoshi Kogure, Sae Yumita, Takamasa Ishino, Keita Ogawa, Terunao Iwanaga, Miyuki Nakagawa, Kisako Fujiwara, Ryuta Kojima, Keisuke Koroki, Masanori Inoue, Kazufumi Kobayashi, Naoya Kanogawa, Soichiro Kiyono, Masato Nakamura, Takayuki Kondo, Ryo Nakagawa, Shingo Nakamoto, Ryosuke Muroyama, Ei Itobayashi, Masanori Atsukawa, Jun Kato, Naoya Kato
Publikováno v:
Drugs - Real World Outcomes, Vol 10, Iss 4, Pp 513-520 (2023)
Abstract Background Cabozantinib was found to be effective as a second- or third-line treatment after sorafenib in patients with advanced hepatocellular carcinoma (HCC) in the phase 3 CELESTIAL trial. So far, as immunotherapy has substituted molecula
Externí odkaz:
https://doaj.org/article/48e468f6fb3749d39b8be35352b06933
Autor:
Takayuki Kondo, Kisako Fujiwara, Miyuki Nakagawa, Kentaro Fujimoto, Sae Yumita, Takamasa Ishino, Keita Ogawa, Terunao Iwanaga, Keisuke Koroki, Hiroaki Kanzaki, Masanori Inoue, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Sadahisa Ogasawara, Shingo Nakamoto, Tetsuhiro Chiba, Jun Kato, Naoya Kato
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-8 (2023)
Abstract The effect of the combination of atezolizumab and bevacizumab (Atez/Bev) for hepatocellular carcinoma (HCC) on pulmonary arterial hypertension (PAH) is unknown. Estimation of PAH by using computed tomography (CT) has recently been proposed.
Externí odkaz:
https://doaj.org/article/de4d5e3fc7164a0cb2c301cc50e1d96f
Autor:
Issei Saeki, Takahiro Yamasaki, Yurika Yamauchi, Tomokazu Kawaoka, Shinsuke Uchikawa, Akira Hiramatsu, Hiroshi Aikata, Kazufumi Kobayashi, Takayuki Kondo, Sadahisa Ogasawara, Tetsuhiro Chiba, Reo Kawano, Kazuaki Chayama, Naoya Kato, Taro Takami
Publikováno v:
Cancer Medicine, Vol 12, Iss 9, Pp 10625-10635 (2023)
Abstract Aim Skeletal muscle volume has been reported to be an important factor that determines overall survival (OS) and post‐progression survival (PPS) in patients with hepatocellular carcinoma (HCC). However, the impact of skeletal muscle volume
Externí odkaz:
https://doaj.org/article/264ad3bdf8c3415999ff96b985e4fa87
Autor:
Sae Yumita, Sadahisa Ogasawara, Miyuki Nakagawa, Susumu Maruta, Tomomi Okubo, Norio Itokawa, Yotaro Iino, Masamichi Obu, Yuki Haga, Atsuyoshi Seki, Tadayoshi Kogure, Takamasa Ishino, Keita Ogawa, Kisako Fujiwara, Terunao Iwanaga, Naoto Fujita, Takafumi Sakuma, Ryuta Kojima, Hiroaki Kanzaki, Keisuke Koroki, Masanori Inoue, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Tomoko Saito, Takayuki Kondo, Ryo Nakagawa, Shingo Nakamoto, Ryosuke Muroyama, Tetsuhiro Chiba, Ei Itobayashi, Masanori Atsukawa, Yoshihiro Koma, Ryosaku Azemoto, Kenji Ito, Hideaki Mizumoto, Jun Kato, Naoya Kato
Publikováno v:
BMC Gastroenterology, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background Hyperprogressive disease (HPD) is a phenomenon with greatly accelerated tumor growth and clinical deterioration rates compared to pre-therapy, in patients treated with immune checkpoint inhibitors (ICI). The aim of this study is t
Externí odkaz:
https://doaj.org/article/e6438030eab2449d8f1c4414595c6e53
Autor:
Naoya Kanogawa, Sadahisa Ogasawara, Susumu Maruta, Yotaro Iino, Masamichi Obu, Takamasa Ishino, Keita Ogawa, Sae Yumita, Terunao Iwanaga, Hidemi Unozawa, Miyuki Nakagawa, Kisako Fujiwara, Takafumi Sakuma, Naoto Fujita, Ryuta Kojima, Hiroaki Kanzaki, Keisuke Koroki, Kazufumi Kobayashi, Masanori Inoue, Soichiro Kiyono, Masato Nakamura, Takayuki Kondo, Tomoko Saito, Ryo Nakagawa, Shingo Nakamoto, Ryosuke Muroyama, Tetsuhiro Chiba, Ei Itobayashi, Yoshihiro Koma, Ryosaku Azemoto, Jun Kato, Naoya Kato
Publikováno v:
BMC Gastroenterology, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Purpose Ramucirumab was shown to be effective as a second-line treatment after sorafenib in patients with advanced hepatocellular carcinoma (HCC) with alpha-fetoprotein levels > 400 ng/mL in a worldwide phase 3 trial. Ramucirumab is used in
Externí odkaz:
https://doaj.org/article/ec4cc9154a2f40df8dcaa61493fe4d89
Autor:
Keisuke Kakisaka, Nobuaki Nakayama, Kotaro Kumagai, Takuro Hisanaga, Takayuki Kondo, Toru Setsu, Shunsuke Sato, Yohei Kooka, Kei Endo, Yuichi Yoshida, Takayoshi Oikawa, Hidekatsu Kuroda, Akio Miyasaka, Ryuzo Abe, Taka-aki Nakada, Yoshihiro Ikura, Kenichi Harada, Takuya Genda, Shuji Terai, Naoya Kato, Taro Takami, Akio Ido, Satoshi Mochida, Takayuki Matsumoto, Atsushi Tanaka
Publikováno v:
Gastro Hep Advances, Vol 2, Iss 4, Pp 497-504 (2023)
Background and Aims: Acute liver injury (ALI) due to autoimmune hepatitis (AIH) can be treated by immunosuppression. In contrast, idiosyncratic drug-induced liver injury (DILI) had a poor prognosis. DILI thus needs to be distinguished from non-DILI.
Externí odkaz:
https://doaj.org/article/41e7930ab9084fc1bab5aaa463fc1040
Autor:
Takayuki Kondo, Kisako Fujiwara, Miyuki Nakagawa, Hidemi Unozawa, Terunao Iwanaga, Takafumi Sakuma, Naoto Fujita, Keisuke Koroki, Hiroaki Kanzaki, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Tomoko Saito, Sadahisa Ogasawara, Eiichiro Suzuki, Yoshihiko Ooka, Shingo Nakamoto, Tetsuhiro Chiba, Makoto Arai, Jun Kato, Naoya Kato
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-9 (2022)
Abstract The screening of gastroesophageal varices (GEV) is critical in hepatocellular carcinoma (HCC) management. Contrast-enhanced computed tomography (CECT) is often performed in patients with HCC. Therefore, this study aimed to examine the use of
Externí odkaz:
https://doaj.org/article/195628a7649a45c4815c5e21e0540138